ΔNp73/ETS2 complex drives glioblastoma pathogenesis— targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma

p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms

(2018) Polina Vikhreva et al.   JOURNAL OF MOLECULAR BIOLOGY

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

(2017) Allison S. Harney et al.   MOLECULAR CANCER THERAPEUTICS

Identifying novel therapeutic agents using xenograft models of pediatric cancer

(2016) Raushan T. Kurmasheva et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FOXD1–ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells

(2016) Peng Cheng et al.   CANCER RESEARCH

Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation

(2016) Zunamys I. Carrero et al.   Oncotarget

TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1

(2016) M. B. Hossain et al.   Science Advances

Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin

(2016) Annamarie C. Dalton et al.   PLoS One

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

(2015) Véronique Diéras et al.   BREAST

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

(2015) Jiajun Zhu et al.   NATURE

Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype

(2015)   Oncotarget

How theTP53Family ProteinsTP63andTP73Contribute to Tumorigenesis: Regulators and Effectors

(2014) Eleonora Candi et al.   HUMAN MUTATION

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

(2014) Bradley J Monk et al.   LANCET ONCOLOGY

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53

(2014) S. Xiong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Extracellular Matrix Structure and Tissue Stiffness Control Postnatal Lung Development through the Lipoprotein Receptor–Related Protein 5/Tie2 Signaling System

(2013) Tadanori Mammoto et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3

(2013) P. Mao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant p53 cooperates with ETS2 to promote etoposide resistance

(2012) P. M. Do et al.   GENES & DEVELOPMENT

ΔNp73 Enhances Promoter Activity of TGF-β Induced Genes

(2012) Maarten Niemantsverdriet et al.   PLoS One

Angiopoietin-4 Promotes Glioblastoma Progression by Enhancing Tumor Cell Viability and Angiogenesis

(2010) M. K. Brunckhorst et al.   CANCER RESEARCH

Isoform-specific p73 knockout mice reveal a novel role for  Np73 in the DNA damage response pathway

(2010) M. T. Wilhelm et al.   GENES & DEVELOPMENT

p63 and p73, the Ancestors of p53

(2010) V. Dotsch et al.   Cold Spring Harbor Perspectives in Biology

DeltaNp73 regulates neuronal survival in vivo

(2009) F. Tissir et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions

(2008) R. Tomasini et al.   GENES & DEVELOPMENT